01:56 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
19:25 , Dec 21, 2018 |  BC Week In Review  |  Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
14:04 , Dec 19, 2018 |  BC Extra  |  Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
02:09 , Feb 17, 2018 |  BioCentury  |  Politics, Policy & Law

FDA’s bigger piggy bank

FDA plans to use a proposed record-setting funding boost to invest in projects it believes could lead to fundamental improvements in the way medical products are tested, reviewed and manufactured. The goal is to use...
23:17 , Sep 29, 2017 |  BioCentury  |  Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
20:50 , Mar 31, 2017 |  BioCentury  |  Finance

It takes two

Third Rock set up Tango Therapeutics Inc. and provided it with a $55 million A round to use advanced technologies to industrialize the discovery of targets and compounds that can induce synthetic lethality. While several...
07:00 , Jul 27, 2015 |  BioCentury  |  Strategy

Rules of competition

Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where - even in Orphan diseases - a better product can steal market share. The reason is that...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

biOasis deal

biOasis said its biOasis Advanced Technologies Inc. subsidiary acquired undisclosed IP from an undisclosed company for C$25,000 ($25,478) in cash, plus five-year warrants to purchase 350,000 shares at C$0.58 and 100,000 shares at C$0.50. If...
07:00 , Oct 1, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of schizophrenia Mice with a mutation that impairs phosphorylation of the NMDA receptor NR1 subtype (GRIN1; NR1) could help guide the development of...